A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Organon & Co. (“Organon,” the “Company,” “we,” “our,” or “us”) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across women’s health and general medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 countries and territories. We sell these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers such as health maintenance organizations, pharmacy benefit managers and other institutions. We operate six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom (“UK”).
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 6.2B | 6.2B | 6.4B | 6.3B | 6.2B | 6.3B |
| Net Income | 187M | 187M | 864M | 1.0B | 917M | 1.4B |
| EPS | $0.72 | $0.72 | $3.33 | $3.99 | $3.59 | $5.31 |
| Free Cash Flow | 538M | 538M | 764M | 548M | 662M | 2.0B |
| ROIC | 4.6% | 6.3% | 15.8% | 15.5% | 15.9% | 22.8% |
| Gross Margin | 53.3% | 53.3% | 58.0% | 59.8% | 62.8% | 62.2% |
| Debt/Equity | 11.70 | 11.70 | 19.14 | -127.59 | -10.22 | -7.06 |
| Dividends/Share | $0.34 | $0.34 | $1.12 | $1.12 | $1.12 | $0.56 |
| Operating Income | 929M | 929M | 1.3B | 1.2B | 1.5B | 1.8B |
| Operating Margin | 14.9% | 14.9% | 20.7% | 19.2% | 25.0% | 28.3% |
| ROE | 24.9% | 30.6% | 429.9% | -212.7% | -76.4% | 67.9% |
| Shares Outstanding | 260M | 260M | 259M | 256M | 255M | 254M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 7.8B | 6.5B | 6.3B | 6.2B | 6.3B | 6.4B | 6.2B | 6.2B |
| Gross Margin | 70.8% | 67.6% | 62.2% | 62.8% | 59.8% | 58.0% | 53.3% | 53.3% |
| R&D | 220M | 210M | 443M | 471M | 528M | 469M | 366M | 366M |
| SG&A | 1.4B | 1.4B | 1.7B | 1.7B | 1.9B | 1.8B | 1.7B | 1.7B |
| EBIT | 3.6B | 2.7B | 1.8B | 1.5B | 1.2B | 1.3B | 929M | 929M |
| Op. Margin | 46.4% | 40.7% | 28.3% | 25.0% | 19.2% | 20.7% | 14.9% | 14.9% |
| Net Income | 3.2B | 2.2B | 1.4B | 917M | 1.0B | 864M | 187M | 187M |
| Net Margin | 41.4% | 33.1% | 21.4% | 14.9% | 16.3% | 13.5% | 3.0% | 3.0% |
| Non-Recurring | 78M | 60M | 10M | 37M | 62M | 31M | 396M | 396M |
| Returns on Capital | ||||||||
| ROIC | N/A | 34.8% | 22.8% | 15.9% | 15.5% | 15.8% | 6.3% | 4.6% |
| ROE | N/A | 34.5% | 67.9% | -76.4% | -212.7% | 429.9% | 30.6% | 24.9% |
| ROA | N/A | 42.3% | 13.0% | 8.5% | 8.9% | 6.9% | 1.4% | 1.5% |
| Cash Flow | ||||||||
| Op. Cash Flow | 3.0B | 2.3B | 2.2B | 858M | 799M | 939M | 700M | 700M |
| Free Cash Flow | 2.9B | 2.0B | 2.0B | 662M | 548M | 764M | 538M | 538M |
| Owner Earnings | 2.6B | 1.4B | 1.2B | -119M | -319M | -226M | -616M | -616M |
| CapEx | 92M | 255M | 192M | 196M | 251M | 175M | 162M | 162M |
| Maint. CapEx | 333M | 820M | 882M | 902M | 1.0B | 1.1B | 1.2B | 1.2B |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 333M | 820M | 882M | 902M | 1.0B | 1.1B | 1.2B | 1.2B |
| CapEx/OCF | N/A | N/A | 8.9% | 22.8% | 31.4% | 18.6% | 23.1% | 23.1% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 145M | 290M | 294M | 297M | 88M | 88M |
| Dividend Yield | N/A | N/A | 2.1% | 4.3% | 6.3% | 6.6% | 3.2% | 3.9% |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 41M | 40M | 59M | 75M | 101M | 105M | 77M | 77M |
| Debt Repayment | 0 | 0 | 112M | 108M | 338M | 1.2B | 1.5B | 1.5B |
| Balance Sheet | ||||||||
| Net Debt | 0 | -12M | 9.9B | 8.4B | 8.2B | 8.4B | 8.2B | 8.2B |
| Cash & Equiv. | 0 | 12M | 737M | 706M | 693M | 675M | 574M | 574M |
| Long-Term Debt | 0 | 0 | 9.1B | 8.9B | 8.8B | 8.9B | 8.6B | 8.6B |
| Debt/Equity | N/A | 0.00 | -7.06 | -10.22 | -127.59 | 19.14 | 11.70 | 11.70 |
| Interest Coverage | N/A | N/A | 6.9 | 3.7 | 2.3 | 2.6 | 1.8 | 1.8 |
| Equity | N/A | 5.5B | -1.5B | -892M | -70M | 472M | 752M | 752M |
| Total Assets | N/A | 10.1B | 10.7B | 11.0B | 12.1B | 13.1B | 12.9B | 12.9B |
| Total Liabilities | N/A | 4.6B | 12.2B | 11.8B | 12.1B | 12.6B | 12.1B | 12.1B |
| Intangibles | N/A | 503M | 651M | 649M | 533M | 1.4B | 1.1B | 1.1B |
| Retained Earnings | N/A | 0 | -998M | -331M | 443M | 1.0B | 1.1B | 1.1B |
| Working Capital | N/A | 894M | 1.2B | 1.4B | 1.6B | 1.6B | 2.0B | 2.0B |
| Current Assets | 105M | 3.6B | 3.8B | 3.9B | 4.5B | 4.3B | 4.4B | 4.4B |
| Current Liabilities | N/A | 2.7B | 2.6B | 2.5B | 2.9B | 2.7B | 2.4B | 2.4B |
| Per Share Data | ||||||||
| EPS | 12.69 | 8.52 | 5.31 | 3.59 | 3.99 | 3.33 | 0.72 | 0.72 |
| Owner EPS | 10.43 | 5.62 | 4.79 | -0.47 | -1.24 | -0.87 | -2.37 | -2.37 |
| Book Value | N/A | 21.64 | -5.93 | -3.49 | -0.27 | 1.82 | 2.90 | 2.90 |
| Cash Flow/Share | 11.91 | 9.01 | 8.49 | 3.36 | 3.12 | 3.62 | 2.70 | 5.49 |
| Dividends/Share | 0.00 | 0.00 | 0.56 | 1.12 | 1.12 | 1.12 | 0.34 | 0.34 |
| Shares Out. | 253.6M | 253.5M | 254.4M | 255.4M | 256.4M | 259.5M | 259.7M | 259.7M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | 4.7 | 6.6 | 3.3 | 4.4 | 9.9 | 12.1 |
| P/FCF | N/A | N/A | 3.2 | 9.2 | 6.2 | 5.0 | 3.5 | 4.2 |
| EV/EBIT | N/A | N/A | 7.8 | 8.8 | 9.0 | 8.6 | 78.8 | 11.3 |
| Price/Book | N/A | N/A | N/A | N/A | N/A | 8.1 | 2.5 | 3.0 |
| Price/Sales | N/A | N/A | 1.1 | 1.1 | 0.8 | 0.7 | 0.4 | 0.4 |
| FCF Yield | N/A | N/A | 31.2% | 10.9% | 16.1% | 20.1% | 28.9% | 23.8% |
| Market Cap | 0 | N/A | 6.3B | 6.1B | 3.4B | 3.8B | 1.9B | 2.3B |
| Avg. Price | 0.00 | N/A | 26.65 | 26.33 | 18.33 | 17.47 | 10.74 | 8.70 |
| Year-End Price | 0.00 | N/A | 24.82 | 23.81 | 13.26 | 14.65 | 7.16 | 8.70 |
Organon & Co. passes 5 of 9 quality checks, suggesting mixed fundamentals.
Organon & Co. trades at 12.1x trailing earnings, compared to its 15-year median P/E of 4.7x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 4.2x vs a median of 5.0x. The company's 5-year average ROIC is 15.2% with a gross margin of 59.2%. Total shareholder yield (dividends) is 3.9%. At current prices, the estimated annualized return to fair value is -23.6%.
Organon & Co. (OGN) has a current P/E ratio of 12.1, compared to its historical median P/E of 4.7. The stock is currently considered Expensive based on its historical valuation range.
Organon & Co. (OGN) has a 5-year average return on invested capital (ROIC) of 15.2%. This indicates strong capital allocation and a potential competitive advantage.
Organon & Co. (OGN) has a market capitalization of $2.3B. It is classified as a mid-cap stock.
Yes, Organon & Co. (OGN) pays a dividend with a trailing twelve-month yield of 3.89%.
Based on historical P/E analysis, Organon & Co. (OGN) appears expensive. The current P/E of 12.1 is 159% above its historical median of 4.7. The estimated fair value CAGR (P/E method) is -18.3%.
Organon & Co. (OGN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Organon & Co. (OGN) reported annual revenue of $6.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
Organon & Co. (OGN) has a net profit margin of 3.0%. This is a modest margin.
Organon & Co. (OGN) generated $538 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Organon & Co. (OGN) has a debt-to-equity ratio of 11.70. This indicates higher leverage, which may increase financial risk.
Organon & Co. (OGN) reported earnings per share (EPS) of $0.72 in its most recent fiscal year.
Organon & Co. (OGN) has a return on equity (ROE) of 30.6%. This indicates the company generates strong returns for shareholders.
Organon & Co. (OGN) has a 5-year average gross margin of 59.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 7 years of financial data for Organon & Co. (OGN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Organon & Co. (OGN) has a book value per share of $2.90, based on its most recent annual SEC filing.